Discounted Cash Flow
P3 Health Partners Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2019 | $145.5m | $0 | $-29.7m | 0.0% | — |
| 2020 | $491.1m (237.5%) | $0 | $-27.5m (7.5%) | 0.0% | — |
| 2021 | $578.6m (17.8%) | $-146.4m | $-54.4m (-97.7%) | -25.3% | — |
| 2022 | $1.0b (81.4%) | $-1.3b (-782.1%) | $-128.3m (-135.7%) | -123.1% (-386.3%) | $-6.50 |
| 2023 | $1.3b (20.7%) | $-128.7m (90.0%) | $-77.9m (39.3%) | -10.2% (91.7%) | $-1.96 (69.8%) |
| 2024 | $1.5b (18.5%) | $-174.5m (-35.7%) | $-110.1m (-41.5%) | -11.6% (-14.5%) | $-2.14 (-8.8%) |
| 2025 | $1.5b (-2.8%) | $-175.1m (-0.3%) | $-91.3m (17.1%) | -12.0% (-3.2%) | $-98.83 (-4522.8%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.